BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. Biohaven Pharmaceutical Holding Company Ltd. Stock
Equities
BHVN
VGG111961055
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.99 USD | -7.52% |
|
-26.54% | -74.31% |
| Apr. 18 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
| Apr. 18 | Biohaven Prices $230 Million Public Share Offering | MT |
Financials (USD)
| Sales 2020 | 63.63 | Sales 2021 | 462.51 | Capitalization | 9.03B |
|---|---|---|---|---|---|
| Net income 2020 | -767M | Net income 2021 | -847M | EV / Sales 2020 | 87,534,473 x |
| Net Debt 2020 | 432M | Net Debt 2021 | 860M | EV / Sales 2021 | 21,377,123 x |
| P/E ratio 2020 |
-6.56
x | P/E ratio 2021 |
-10.5
x | Employees | 928 |
| Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 90.13% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -7.52% | ||
| Current month | -74.31% | ||
| Current year | -74.31% |
3 years
37.61
152.56
5 years
26.56152.56
10 years
16.50152.56
| Managers | Title | Age | Since |
|---|---|---|---|
Paloma Moraleda
PSD | President | - | 22-10-02 |
Jon Blaskovich
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Compliance Officer | - | 17-10-24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paloma Moraleda
PSD | President | - | 22-10-02 |
Gastón Ortega
BRD | Director/Board Member | - | 22-10-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.97% | 0 M€ | 0.00% | - | |
| 0.11% | 9 M€ | -.--% | - | |
| 0.06% | 736 M€ | +4.84% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 38.99 | -7.52% | 3,353,231 |
| 24-04-18 | 42.16 | -4.25% | 3,668,414 |
| 24-04-17 | 44.03 | +0.59% | 1,040,176 |
| 24-04-16 | 43.77 | -2.23% | 1,955,136 |
| 24-04-15 | 44.77 | -15.66% | 3,401,934 |
Delayed Quote Nyse, April 19, 2024 at 04:00 pm EDT
More quotes
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based commercial-stage biopharmaceutical company. The Company has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.
| 1st Jan change | Capi. | |
|---|---|---|
| -74.31% | 541M | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- BHVN Stock
